Efficacy of Combination of Camrelizumab with Anlotinib as Third-line Therapy for Patients with Advanced Non-small Cell Lung Cancer
-
摘要:目的
探讨卡瑞利珠单抗联合安罗替尼三线治疗晚期非小细胞肺癌的临床疗效及安全性。
方法回顾性分析84例二线治疗进展后的晚期非小细胞肺癌患者的临床资料。其中44例接受卡瑞利珠单抗联合安罗替尼治疗的患者为观察组，40例接受单药安罗替尼治疗的患者为对照组。比较两组无进展生存期（PFS）、客观缓解率（ORR）、疾病控制率（DCR）和不良事件（AE）发生率。
结果观察组的中位PFS长于对照组（7.0月vs. 5.6月, P=0.001）。两组ORR及DCR差异无统计学意义（P=0.112, P=0.508）。两组AE及≥3级AE发生率差异均无统计学意义（P=0.222, P=0.112）。
结论卡瑞利珠单抗联合安罗替尼三线治疗晚期非小细胞肺癌的临床疗效优于单用安罗替尼，且安全性良好。
Abstract:ObjectiveTo investigate the clinical efficacy and related adverse reactions of the combination of camrelizumab with anlotinib as the third-line therapy on advanced non-small cell lung cancer.
MethodsWe retrospectively analyzed the clinical data of 84 patients with advanced non-small cell lung cancer after second-line treatment. According to different treatment methods, 44 patients who received camrelizumab combined with anlotinib were included in the observation group, and 40 patients who received anlotinib alone were included in the control group. The PFS, ORR, DCR and incidence of adverse reactions were analyzed and compared between the two groups.
ResultsThe median PFS of the observation group was longer than that of the control group (7.0 vs. 5.6 months, P=0.001). No statistically significant difference was observed in ORR, DCR, the incidence of adverse reactions or the incidence of adverse reactions above grade 3 between two groups (all P > 0.05).
ConclusionThe clinical efficacy of camrelizumab combined with anlotinib as third-line therapy on advanced non-small cell lung cancer is better than anlotinib alone, and the safety is good.
-
Key words:
- Camrelizumab /
- Anlotinib /
- NSCLC /
- Third-line therapy /
- Adverse effect
-
Competing interests: The authors declare that they have no competing interests.利益冲突声明：所有作者均声明不存在利益冲突。作者贡献：张晓娟：选题设计、资料与数据收集、文章撰写和修改岳冬丽：选题设计、数据收集杨双宁、郝娜：数据收集王丽萍、董文杰：指导选题与设计、指导文章写作与修改
-
![]()
图 1 卡瑞利珠单抗联合安罗替尼组与单药安罗替尼组PFS的比较
Figure 1 Comparison of PFS between observation group and control group
表 1 卡瑞利珠单抗联合安罗替尼组与单药安罗替尼组一般临床资料(n(%))
Table 1 General clinical data of camrelizumab combined with anlotinib (observation) group and anlotinib alone (control) group (n(%))
下载: 导出CSV
表 2 卡瑞利珠单抗联合安罗替尼组与单药安罗替尼组患者短期疗效比较(n(%))
Table 2 Comparison of short-term efficacy between observation group and control group (n(%))
下载: 导出CSV
表 3 卡瑞利珠单抗联合安罗替尼组与单药安罗替尼组不良反应发生率比较(n(%))
Table 3 Comparison of the incidence of adverse effects between observation group and group group (n(%))
下载: 导出CSV
表 4 卡瑞利珠单抗联合安罗替尼组与单药安罗替尼组≥3级不良反应发生率比较(n(%))
Table 4 Comparison of the incidence of grade ≥3 adverse reactions between observation group and control group (n(%))
下载: 导出CSV
-
[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2] Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69(5): 363-385. doi: 10.3322/caac.21565
[3] Bonomi PD. Implications of key trials in advanced nonsmall cell lung cancer[J]. Cancer, 2010, 116(5): 1155-1164. doi: 10.1002/cncr.24815
[4] 金振兴, 杜秀平. 盐酸安罗替尼治疗晚期非小细胞肺癌的临床观察[J]. 临床与病理杂志, 2020, 40(4): 905-912. https://www.cnki.com.cn/Article/CJFDTOTAL-WYSB202004016.htm Jin ZX, Du XP. Clinical observation of anlotinib hydrochloride in the treatment of advanced non-small cell lung cancer[J]. Lin Chuang Yu Bing Li Za Zhi, 2020, 40(4): 905-912. https://www.cnki.com.cn/Article/CJFDTOTAL-WYSB202004016.htm
[5] Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci, 2018, 109(4): 1207-1219. doi: 10.1111/cas.13536
[6] 陈海峰. 安罗替尼三线及以上治疗66例中晚期非小细胞肺癌的疗效及影响因素分析[J]. 浙江医学, 2020, 42(14): 1524-1528. doi: 10.12056/j.issn.1006-2785.2020.42.14.2020-1198 Chen HF. Efficacy of anlotinib as third-line treatment and above for patients with advanced non-small cell lung cancer[J]. Zhejiang Yi Xue, 2020, 42(14): 1524-1528. doi: 10.12056/j.issn.1006-2785.2020.42.14.2020-1198
[7] 涂建仁, 付华珍. 卡瑞利珠单抗联合化疗一线治疗晚期/转移性非鳞状非小细胞肺癌疗效观察[J]. 药品评价, 2020, 17(19): 38-40. doi: 10.3969/j.issn.1672-2809.2020.19.012 Tu JR, Fu HZ. Efficacy of Camrelizumab Combined with First-line Chemotherapy in Treatment of Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer[J]. Yao Pin Ping Jia, 2020, 17(19): 38-40. doi: 10.3969/j.issn.1672-2809.2020.19.012
[8] 周永慧, 陈鸿志. 免疫检查点抑制剂联合放化疗在晚期非小细胞肺癌治疗中的研究进展[J]. 临床肿瘤学杂志, 2021, 26(10): 947-954. doi: 10.3969/j.issn.1009-0460.2021.10.014 Zhou YH, Chen HZ. Progression of immune checkpoint inhibitors combined with chemoradiotherapy in the treatment ofadvanced non-small cell lung cancer[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2021, 26(10): 947-954. doi: 10.3969/j.issn.1009-0460.2021.10.014
[9] Liang H, Wang M. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer[J]. Cancer Manag Res, 2019, 11: 7707-7719. doi: 10.2147/CMAR.S212238
[10] 王婧怡, 彭文颖, 江美林, 等. 抗血管生成药物联合免疫检查点抑制剂治疗晚期非小细胞肺癌的研究进展[J]. 中国肺癌杂志, 2021, 24(3): 196-203. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202103008.htm Wang JY, Peng WY, Jiang ML, et al. Research Progress of Anti-angiogenic Agents Combined with Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer[J]. Zhongguo Fei Ai Za Zhi, 2021, 24(3): 196-203. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202103008.htm
[11] 宋羽霄, 章必成. 免疫联合抗血管生成: 肿瘤治疗的新策略[J]. 医药导报, 2020, 39(8): 1068-1072. https://www.cnki.com.cn/Article/CJFDTOTAL-YYDB202008009.htm Song YX, Zhang BC. Anti-angiogenic Agents in Combination with Immune Checkpoint Inhibitors: APromising Strategy for Cancer Treatment[J]. Yi Yao Dao Bao, 2020, 39(8): 1068-1072. https://www.cnki.com.cn/Article/CJFDTOTAL-YYDB202008009.htm
[12] Qin S, Ren Z, Feng Y, et al. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study[J]. Liver Cancer, 2021, 10(4): 296-308. doi: 10.1159/000513486
[13] 齐瑞丽, 张勇丹, 王华庆, 等. 免疫检查点抑制剂联合抗血管生成治疗恶性肿瘤的作用机制[J]. 临床肿瘤学杂志, 2020, 25(7): 664-668. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL202007014.htm Qi RL, Zhang YD, Wang HQ, et al. Mechanism of immune checkpoint inhibitor combined with antiangiogenic therapy in the treatment of malignanttumors[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2020, 25(7): 664-668. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL202007014.htm
[14] 程颖. 晚期非小细胞肺癌免疫治疗的研究进展[J]. 肿瘤防治研究, 2021, 48(8): 745-750. doi: 10.3971/j.issn.1000-8578.2021.21.0472 Cheng Y. Research Progress of Immunotherapy for Advanced Non-small Cell Lung Cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2021, 48(8): 745-750. doi: 10.3971/j.issn.1000-8578.2021.21.0472
[15] Herbst RS, Arkenau HT, Bendell J, et al. Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC[J]. J Thorac Oncol, 2021, 16(2): 289-298.
[16] Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. [J]. Lancet Respir Med, 2019, 7(5): 387-401.
[17] 龙方园, 何芳, 涂洁, 等. PD-1抑制剂(卡瑞利珠单抗)致反应性毛细血管增生症三例并文献复习[J]. 中国麻风皮肤病杂志, 2020, 36(4): 219-223. https://www.cnki.com.cn/Article/CJFDTOTAL-MALA202004009.htm Long FY, He F, Tu J, et al. Reactive capillary hemangiomas caused by PD-1 inhibitor (Calerizumab): a report of three cases and literature review[J]. Zhongguo Ma Feng Pi Fu Bing Za Zhi, 2020, 36(4): 219-223. https://www.cnki.com.cn/Article/CJFDTOTAL-MALA202004009.htm
[18] Chen X, Ma L, Wang X, et al. Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210[J]. Cancer Biol Med, 2019, 16(1): 173-181.
[19] Finlay WJJ, Coleman JE, Edwards JS, et al. Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement[J]. MAbs, 2019, 11(1): 26-44.
计量
- 文章访问数: 2514
- HTML全文浏览量: 617
- PDF下载量: 442
